Respiratory

Back to articles

Nintedanib shown to slow lung function decline in patients with systemic sclerosis lung disease

KEY POINT

Treatment with nintedanib (Ofev—Boehringer Ingelheim) slowed the rate of decline in pulmonary function in adults with interstitial lung disease (ILD) associated with systemic sclerosis, according to a study published in the New England Journal of Medicine.

SOURCES

Distler O, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–28.